Record 01 Week of 5 October 2026 · REGULATION Six peptides recommended for the 503A bulks list · REGULATION From Category 2 to review: how twelve peptides came off the restricted list · REGULATION FDA proposes to end 503B compounding of semaglutide, tirzepatide and liraglutide · TRIALS Retatrutide: four Phase 3 readouts in 2026 · TRIALS Orforglipron approved; the oral GLP-1 question · PAPERS GLP-1 drugs recruit hunger neurons to sustain fat loss, Yale study finds · PAPERS A peptide–drug conjugate that hits five targets, in mice · PAPERS What GLP-1 users do differently: activity, bone and persistence · EVIDENCE BPC-157: what the human record contains · PUBLIC AND POLICY A public-health school explains the peptides in the feed · PUBLIC AND POLICY The gray market and the state patchwork · INDUSTRY Who makes peptides: capacity and ownership moves · Record 01 Week of 5 October 2026 · REGULATION Six peptides recommended for the 503A bulks list · REGULATION From Category 2 to review: how twelve peptides came off the restricted list · REGULATION FDA proposes to end 503B compounding of semaglutide, tirzepatide and liraglutide · TRIALS Retatrutide: four Phase 3 readouts in 2026 · TRIALS Orforglipron approved; the oral GLP-1 question · PAPERS GLP-1 drugs recruit hunger neurons to sustain fat loss, Yale study finds · PAPERS A peptide–drug conjugate that hits five targets, in mice · PAPERS What GLP-1 users do differently: activity, bone and persistence · EVIDENCE BPC-157: what the human record contains · PUBLIC AND POLICY A public-health school explains the peptides in the feed · PUBLIC AND POLICY The gray market and the state patchwork · INDUSTRY Who makes peptides: capacity and ownership moves ·
Topic primer
Growth-hormone axis
Three compounds act on the same axis with very different evidence: tesamorelin has an approved indication and randomised trials; ipamorelin and CJC-1295 have early human studies from abandoned programmes and little since.
TIMELINE
Sep 2023
Ipamorelin acetate and CJC-1295 placed in Category 2.
Sep 2024
Nominations for CJC-1295 and ipamorelin acetate withdrawn; both leave the 503A Category 2 table. Ipamorelin stays in 503B Category 2.
Oct 2024
Advisory committee votes against adding ipamorelin to the 503A bulks list.
2025–2028
MGH trial of tesamorelin with exercise in HIV recruiting (NCT06554717).
